Cargando…
Ribosome subunit attrition and activation of the p53–MDM4 axis dominate the response of MLL-rearranged cancer cells to WDR5 WIN site inhibition
The chromatin-associated protein WDR5 is a promising target for cancer drug discovery, with most efforts blocking an arginine-binding cavity on the protein called the “WIN” site that tethers WDR5 to chromatin. WIN site inhibitors (WINi) are active against multiple cancer cell types in vitro, the mos...
Autores principales: | Howard, Gregory C., Wang, Jing, Rose, Kristie Lindsey, Patel, Purvi, Tsui, Tina, Florian, Andrea C., Lorey, Shelly L., Grieb, Brian C., Smith, Brianna N., Slota, Macey J., Reynolds, Elizabeth M., Goswami, Soumita, Savona, Michael R., Lee, Taekyu, Fesik, Stephen W., Liu, Qi, Tansey, William P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10402127/ https://www.ncbi.nlm.nih.gov/pubmed/37546802 http://dx.doi.org/10.1101/2023.07.26.550648 |
Ejemplares similares
-
Impact of WIN site inhibitor on the WDR5 interactome
por: Guarnaccia, Alissa D., et al.
Publicado: (2021) -
WIN site inhibition disrupts a subset of WDR5 function
por: Siladi, Andrew J., et al.
Publicado: (2022) -
Synergistic action of WDR5 and HDM2 inhibitors in SMARCB1-deficient cancer cells
por: Florian, Andrea C, et al.
Publicado: (2022) -
Targeting WDR5: A WINning Anti-Cancer Strategy?
por: Aho, Erin R, et al.
Publicado: (2019) -
Displacement of WDR5 from Chromatin by a WIN Site Inhibitor with Picomolar Affinity
por: Aho, Erin R., et al.
Publicado: (2019)